New drug aims to halt liver scarring in early trial

NCT ID NCT06750276

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests an experimental drug called AZD2389 in people with liver fibrosis (scarring) and compensated cirrhosis (early-stage liver damage). The goal is to check the drug's safety and how the body handles it. About 40 adults with liver disease will receive either AZD2389 or a placebo. Researchers will also look for signs that the drug affects the liver.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD2389
What this could lead to: If successful, this could point toward a new treatment to slow or stop liver scarring in people with liver disease.
What could go wrong: This is an early phase 2a trial with only 40 participants, so results may not apply to everyone. The drug may not prove effective or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC CIRRHOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver fibrotic liver disease metabolic dysfunction-associated steatohepatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATIC CIRRHOSIS LIVER FIBROSIS

Contacts and locations

Show contact details

Locations

Research Site

Chandler, Arizona, 85224, United States
Research Site

Rialto, California, 92377, United States
Research Site

Atlanta, Georgia, 30349, United States
Research Site

Morehead City, North Carolina, 28557, United States
Research Site

Houston, Texas, 77079, United States
Research Site

San Antonio, Texas, 78215, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

San Juan, 00927, Puerto Rico
Research Site

Cambridge, CB2 0QQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.